Is a Large-Scale Screening for Alzheimer’s Disease Possible? Yes, in a Few Years

IF 8.5 3区医学 Q1 CLINICAL NEUROLOGY

Jpad-Journal of Prevention of Alzheimers Disease Pub Date : 2019-01-01 DOI:10.14283/jpad.2019.29

Federica Ribaldi, Federica Ribaldi, D. Altomare, Giovanni B. Frisoni

引用次数: 5

Abstract

Recent evidence on blood-based biomarkers is pointing the way towards a new era of large-scale, feasible, cost-effective and non-invasive screening for Alzheimer’s disease (AD). This was one of the main focuses of the recent meeting of the European Union-North American Clinical Trials in AD (EU/US CTAD) Task Force, which took place in Barcelona in October 24-27, 2018, and convened drug and diagnostics developers from industry and academia in order to define a roadmap for the development and marketing of blood-based biomarkers (1).

查看原文本刊更多论文

阿尔茨海默病的大规模筛查可能吗?是的，几年后

基于血液的生物标志物的最新证据为阿尔茨海默病(AD)的大规模、可行、具有成本效益和无创筛查的新时代指明了方向。这是欧盟-北美AD临床试验(EU/US CTAD)工作组最近会议的主要焦点之一，该会议于2018年10月24日至27日在巴塞罗那举行，会议召集了来自工业界和学术界的药物和诊断开发人员，以确定基于血液的生物标志物的开发和营销路线图(1)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Jpad-Journal of Prevention of Alzheimers Disease CLINICAL NEUROLOGY-

自引率

7.80%

发文量

期刊介绍： The JPAD « Journal of Prevention of Alzheimer’Disease » will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and heath economic outcomes. JPAD will publish also the meeting abstracts from Clinical Trial on Alzheimer Disease (CTAD) and will be distributed both in paper and online version worldwide.